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While the world is struggling in a pandemic, the neuro-
oncological community aims at providing the best possible 
care for brain tumor patients. The Covid-19 pandemic imposes 
several additional challenges, including, but not limited to, the 
need for social distancing practices, travel restrictions, and im-
paired access to health care and clinical trials. In the current 
issue of Neuro-Oncology Practice, Fonkem and colleagues re-
viewed telemedicine practices, which have gained increasing 
interest and use in many areas of clinical medicine (p. 109). At 
two large institutions, telemedicine helped to recover patient 
volumes, which had significantly dropped at the beginning of 
the pandemic due to site closures. While telemedicine will not 
replace classical on-site visits and in-person consultations, it 
may represent a helpful tool for the medical care and support 
of patients with limited mobility or other reasons leading to im-
paired follow-up, also beyond the Covid-19 pandemic.
Patients are also more and more frequently looking for 
disease-specific information in the internet. Lim and col-
leagues performed a study of 100 meningioma websites and 
determined their content, data of last update, understanda-
bility for a general population, and responsiveness upon con-
tact (p. 129). While such websites may be a helpful resource 
for patients and relatives, the quality of the provided informa-
tion varies. Physicians may direct patients to selected web-
sites with high-quality content and regular updates.
The MD Anderson Symptom Inventory Brain Tumor Module 
(MDASI-BT) is a validated patient self-reporting questionnaire 
that has become a valuable tool in daily practice and clinical 
trials. Piil and colleagues performed a validation process for 
the Danish version of this questionnaire in a cohort of 120 
patients (p. 137). The results of the study confirm the validity 
of the Danish questionnaire as well as its utility for patient 
assessment.
In a related article, Garnier et  al. analyzed the quality of 
patient-reported outcome (PRO) data in randomized con-
trolled trials for glioblastoma patients (p. 148). Although the 
Consolidated Standards of Reporting Trials (CONSORT) state-
ment was extended with a PRO section, aiming at improving 
the quality of this reporting, only minor improvements were 
observed over time in 44 trials. A more thorough analysis of 
PRO in ongoing and future trials should be sought.
Cognitive impairment is one of the most frequent findings 
in brain tumor patients, resulting in reduced quality of life. 
Particularly in patients with a life expectancy of years or even 
decades, cognitive sequelae caused by the tumor or the ad-
ministered therapy require intense attention. Weyer-Jamora 
and colleagues provide an overview of the most frequently af-
fected cognitive domains in patients with lower-grade glioma 
and discuss rehabilitation strategies that may help to reduce 
these deficits (p. 117). Cognitive impairment of brain tumor 
patients is also of considerable importance for relatives. This 
topic was addressed by Gosselt and colleagues in a survey, 
which revealed that there might be significant differences be-
tween the patients’ and relatives’ perception of cognitive com-
plaints (p. 160).
The perspective of relatives and caregivers with a focus on 
the end-of-life phase of glioma patients is reported in an ar-
ticle by Fortunato and colleagues (p. 171). A total of 41 family 
caregivers completed a structured interview that addressed 
physical comfort and emotional support, advanced care plan-
ning and other aspects. Most caregivers were satisfied with 
end-of-life care. However, it is important to note that less than 
50% of the interviewed persons knew what to do at the time 
of the patient’s death, indicating a need for better patient and 
caregiver education.
In a similar approach, Jeon and colleagues explored sleep 
disturbances in patients with malignant brain tumors and their 
family caregivers (p. 179). The results of the semi-structured 
interviews revealed that most participants had difficulties in 
initiating and maintaining sleep. In patients and caregivers, 
anxiety because of the brain tumor diagnosis, treatment, and 
caregiver burden were viewed as the underlying causal fac-
tors. Similar to the previous article, the results of this analysis 
point to a need for better patient and caregiver education re-
garding sleep disturbances and potential coping and treat-
ment strategies.
Radiotherapy remains a cornerstone in the treatment of 
many brain tumors. However, depending on the tumor en-
tity and other available treatment options, there remain sev-
eral open questions. Teyateeti and colleagues performed a 
retrospective analysis of 51 patients diagnosed with a grade 














































































underwent irradiation of the parenchymal bed only or the 
parenchymal and dural resection area. Virtually all patients 
experienced tumor recurrence, mostly in the parenchymal 
resection cavity. Isolated dural recurrence was not ob-
served. Median progression-free and overall survival were 
not different between the two groups, suggesting that 
omission of dural irradiation may be considered. As cor-
rectly noted by the authors, larger and prospective studies 
are needed to confirm these findings.
Radiotherapy is also part of the standard treatment in pa-
tients with newly diagnosed glioblastoma. Al Feghali and 
colleagues interrogated the National Cancer Database for gli-
oblastoma patients aged 60 or older and analyzed the impact 
of various factors, including therapeutic management, on pa-
tients’ outcome (p. 199). As observed in many studies before, 
KPS was confirmed as a strong prognostic factor and com-
bined radiochemotherapy was associated with better outcome.
Rare brain tumors and molecular alterations only found 
in small subsets of tumors have gained increasing interest 
in the past few years as more and more specific treatment 
options become available that might be beneficial for 
selected patients. While classical immunohistochemistry 
is becoming more frequently replaced by molecular ana-
lyses, Schittenhelm and colleagues demonstrate that it 
may still be a helpful and easily applied technique that 
allows for screening of fibroblast growth factor receptor 
(FGFR) 3 alterations in glioma specimens, which may sub-
sequently be used for a targeted therapy approach (p. 209).
Pleomorphic xanthoastrocytoma (PXA) is a rare sub-
type of gliomas and frequently harbors BRAF mutations 
that may be targeted with specific inhibitors. Dono et al. 
analyzed a cohort of 470 patients with a PXA (p. 222). 
Pediatric patients had a more favorable prognosis than 
adult patients. Larger tumor size was also associated with 
shorter overall survival. While the retrospective nature of 
the series did not permit firm conclusions on the activity 
of different treatments, it seemed that gross total resection 
might be associated with better outcome whereas the role 
of radio- and chemotherapy needs to be defined in addi-
tional studies.
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